BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25726505)

  • 1. Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center.
    Necchi A; Farè E; Vullo SL; Giannatempo P; Raggi D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Verzoni E; Grassi P; Procopio G; Pizzocaro G; Mariani L; Salvioni R
    Clin Genitourin Cancer; 2015 Aug; 13(4):385-391.e1. PubMed ID: 25726505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
    Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
    Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thoracic Metastasectomy in Germ Cell Tumor Patients Treated With First-line Versus Salvage Therapy.
    Caso R; Jones GD; Tan KS; Bosl GJ; Funt SA; Sheinfeld J; Reuter VE; Amar D; Fischer G; Molena D; Rocco G; Bains MS; Feldman DR; Jones DR
    Ann Thorac Surg; 2021 Apr; 111(4):1141-1149. PubMed ID: 32882201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database.
    Oing C; Lorch A; Bokemeyer C; Honecker F; Beyer J; Berger LA; Oechsle K
    J Cancer Res Clin Oncol; 2015 May; 141(5):923-31. PubMed ID: 25395217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors that impact the outcomes in testicular germ cell tumors in low-middle-income countries.
    Saju SV; Radhakrishnan V; Ganesan TS; Dhanushkodi M; Raja A; Selvaluxmy G; Sagar TG
    Med Oncol; 2019 Feb; 36(3):28. PubMed ID: 30725328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Characteristics and Treatment Outcomes of Patients With Advanced Germ Cell Tumor Treated at a Tertiary Cancer Center in Brazil.
    Vasconcellos VF; Bastos DA; Pereira AAL; Watarai GY; Pereira BR; de Godoy A; Almeida-Silva J; Muniz DQB; Guglielmetti GB; Nahas WC; Dzik C
    J Glob Oncol; 2019 Feb; 5():1-8. PubMed ID: 30779600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014.
    Adra N; Althouse SK; Liu H; Brames MJ; Hanna NH; Einhorn LH; Albany C
    Ann Oncol; 2016 May; 27(5):875-9. PubMed ID: 26861605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.
    Lewin J; Dickinson M; Voskoboynik M; Collins M; Ritchie D; Toner G
    Intern Med J; 2014 Aug; 44(8):771-8. PubMed ID: 24893627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation.
    Raggi D; Mariani L; Giannatempo P; Lo Vullo S; Giardiello D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Calareso G; Magni M; Di Nicola M; Verzoni E; Grassi P; Procopio G; De Braud F; Pizzocaro G; Salvioni R; Necchi A
    Urol Oncol; 2015 Jul; 33(7):332.e19-24. PubMed ID: 25985712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study.
    Oing C; Oechsle K; Necchi A; Loriot Y; De Giorgi U; Fléchon A; Daugaard G; Fedyanin M; Faré E; Bokemeyer C
    Ann Oncol; 2017 Mar; 28(3):576-582. PubMed ID: 27993806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
    Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
    Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.
    Feldman DR; Patil S; Trinos MJ; Carousso M; Ginsberg MS; Sheinfeld J; Bajorin DF; Bosl GJ; Motzer RJ
    Cancer; 2012 Feb; 118(4):981-6. PubMed ID: 21792865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
    Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
    N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
    Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
    Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.
    Loriot Y; Pagliaro L; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Laplanche A; Le Teuff G; Culine S; Fizazi K
    Eur J Cancer; 2017 Dec; 87():140-146. PubMed ID: 29149760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study.
    Fizazi K; Oldenburg J; Dunant A; Chen I; Salvioni R; Hartmann JT; De Santis M; Daugaard G; Flechon A; de Giorgi U; Tjulandin S; Schmoll HJ; Bouzy J; Fossa SD; Fromont G
    Ann Oncol; 2008 Feb; 19(2):259-64. PubMed ID: 18042838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy.
    Ko JJ; Bernard B; Tran B; Li H; Asif T; Stukalin I; Lee M; Day D; Alimohamed N; Sweeney CJ; Bedard PL; Heng DY
    J Clin Oncol; 2016 Mar; 34(7):714-20. PubMed ID: 26786931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
    Albany C; Adra N; Snavely AC; Cary C; Masterson TA; Foster RS; Kesler K; Ulbright TM; Cheng L; Chovanec M; Taza F; Ku K; Brames MJ; Hanna NH; Einhorn LH
    Ann Oncol; 2018 Feb; 29(2):341-346. PubMed ID: 29140422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.
    Kawai K; Hinotsu S; Oikawa T; Sekido N; Hattori K; Miyanaga N; Hasegawa Y; Kojima H; Shimazui T; Akaza H
    Jpn J Clin Oncol; 2006 Nov; 36(11):723-30. PubMed ID: 17082218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome and predictors of survival in late relapse of germ cell tumor.
    Sharp DS; Carver BS; Eggener SE; Kondagunta GV; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2008 Dec; 26(34):5524-9. PubMed ID: 18936477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.